Cellectar Biosciences, Inc.
General ticker "CLRB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $15.6M (TTM average)
Cellectar Biosciences, Inc. does not follow the US Stock Market performance with the rate: -18.7%.
Estimated limits based on current volatility of 4.6%: low 1.19$, high 1.30$
Factors to consider:
- Earnings expected soon, date: 2026-11-10 bmo
- Total employees count: 11 (0.0%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Need additional capital, FDA approval delays, Clinical trial failure, Market competition, Regulatory and compliance
Short-term CLRB quotes
Long-term CLRB plot
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $38.96MM | $51.78MM | $22.98MM |
| Operating Income | $-38.96MM | $-51.78MM | $-22.98MM |
| Non-Operating Income | $-3.87MM | $7.26MM | $1.19MM |
| R&D Expense | $27.27MM | $26.14MM | $11.50MM |
| Income(Loss) | $-42.83MM | $-44.52MM | $-21.79MM |
| Taxes | $-0.06MM | $0.07MM | $0.00MM |
| Net Income(Loss)* | $-42.77MM | $-44.58MM | $-21.79MM |
| Stockholders Equity | $-1.36MM | $14.29MM | $8.54MM |
| Assets | $12.08MM | $25.47MM | $14.98MM |
| Operating Cash Flow | $-32.38MM | $-47.58MM | $-23.12MM |
| Capital expenditure | $0.86MM | $0.10MM | $0.01MM |
| Investing Cash Flow | $-0.86MM | $-0.10MM | $-0.01MM |
| Financing Cash Flow | $22.94MM | $61.41MM | $13.03MM |
| Earnings Per Share** | $-104.99 | $-36.52 | $-8.35 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.